AstraZeneca's COPD Drug Tosarikimab Shows Success in Two Phase 3 Trials

AstraZeneca's chronic obstructive pulmonary disease (COPD) treatment Tosarikimab has met key efficacy endpoints in two late-stage clinical trials. The drug is expected to generate annual maximum revenue of over $5 billion (approximately 6.725 trillion won). AstraZeneca previously announced in March that in Phase 3 OBERON and TITANIA trials, Tosarikimab significantly reduced the rate of COPD exacerbations compared to placebo. CNBC reported on April 8 that the full data released supports Tosarikimab's potential as a next-generation COPD treatment and its projected $5 billion+ annual sales outlook. Tosarikimab is an antibody therapy targeting interleukin-33 (IL-33), an inflammatory signaling molecule. AstraZeneca is also conducting additional clinical trials for COPD drug development.
Korean Source
This article is an English localization of a Korean-language crypto news report. Original headline: 아스트라제네카 COPD 신약 3상 2건 성공…연매출 6.7조원 전망